NCT02129803

Evaluating High Flow Humidification Therapy in Patients With Cystic Fibrosis

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Virginia Commonwealth University · Academic / Other
• Sex: All
• Age: 10 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

This study is a single center, randomized pilot study to evaluate the clinical effectiveness of nasal high flow 20LPM humidification therapy in subjects with Cystic Fibrosis.

Conditions

• Cystic Fibrosis

Interventions

Type	Name	Description
DEVICE	High-Flow, 20 LPM (via Optiflow cannula)	Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.
DEVICE	Low FLow, 5 LPM (via Optiflow cannula)	standard humidified wall medical air.

Timeline

• Start date: 2015-05-01
• Primary completion: 2019-05-29
• Completion: 2019-05-29
• First posted: 2014-05-02
• Last updated: 2021-01-06
• Results posted: 2021-01-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study